Arzoxifene

Drug Profile

Arzoxifene

Alternative Names: Arzoxifene hydrochloride; LY353381; SERM III; SERM-3

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Osteoporosis therapies; Piperidines; Thiophenes
  • Mechanism of Action Selective estrogen receptor agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Ovarian cancer; Peritoneal cancer; Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Sep 2009 Efficacy data from a phase III trial in postmenopausal osteoporosis presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
  • 25 Mar 2009 Efficacy and safety data from the phase III, NEXT trial in Postmenopausal osteoporosis released by Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top